Back to top
more

Jazz Pharmaceuticals PLC (JAZZ)

(Delayed Data from NSDQ)

$170.74 USD

170.74
986,591

-2.76 (-1.59%)

Updated Feb 25, 2021 04:00 PM ET

After-Market: $170.73 -0.01 (-0.01%) 7:48 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (195 out of 253)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.

Kinjel Shah headshot

Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More

Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.

Neena Mishra headshot

Should You Invest in Marijuana Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Cannabis Stocks Rise on Hopes of Federal Legalization in US

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

New Strong Sell Stocks for February 10th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Sweta Killa headshot

Cannabis ETFs Spike on Jazz-GW Pharma Deal

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.

Jazz (JAZZ) Down 3.7% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can Value Investors Consider Jazz Pharmaceuticals (JAZZ) Stock?

Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.

Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance

Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.

Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 6.95% and 4.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Inks Mirvetuximab Development Deal in China

ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.

Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study

Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.

Company News for Oct 9, 2020

Companies in the news are: COTY, EV, AVAV, JAZZ

ImmunoGen's Rare Blood Cancer Candidate Gets Breakthrough Tag

The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Savara to Stop Study on Molgradex for NTM Lung Infection

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

Rimmi Singhi headshot

High Earnings Yield Makes These Stocks Worth Buying Right Now

Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.

Jazz (JAZZ) Up 11.4% Since Last Earnings Report: Can It Continue?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surging Earnings Estimates Signal Upside for Jazz (JAZZ) Stock

Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.